Imawaka Haruo, Ito Kiyomi, Kitamura Yoshiaki, Sugiyama Kiyoshi, Sugiyama Yuichi
Minase Research Institute, ONO Pharmaceutical Co., Ltd., 3-1-1, Sakurai, Shimamoto-cho, Mishima-gun, Osaka, 618-8585, Japan.
Pharm Res. 2009 Aug;26(8):1881-9. doi: 10.1007/s11095-009-9902-6. Epub 2009 May 7.
To predict the absolute oral bioavailabilities (BAs) of drugs in humans without using pharmacokinetic data from intravenous administration in humans.
The distribution volume of the terminal phase (Vd(beta)) in humans was predicted by three methods using animal pharmacokinetic data. Then, total body clearance (CL(tot)) was calculated by multiplying the elimination rate constant and Vd(beta), and the BA was calculated as a ratio between CL(tot) and oral clearance. The predicted and observed values were compared for 67 drugs for which pharmacokinetic data after intravenous administration in humans were available.
For Vd(beta), predicted values within twice the observed value were obtained for 72.1% of drugs by both methods Ia and Ib, respectively, in which only rat pharmacokinetic data were used. The corresponding percentage was 75.0% for method II, in which pharmacokinetic data from animals other than rats were used. For BA, predicted values within 1.3 times the observed values were obtained for 66.7% and 57.4% of drugs by methods Ia and Ib, respectively, and 75.0% by method II.
Using the present methods, it is possible to predict BA from human oral administration data combined with animal pharmacokinetic data to a certain level without using intravenous injection data.
在不使用人体静脉给药药代动力学数据的情况下预测药物在人体中的绝对口服生物利用度(BA)。
采用三种方法利用动物药代动力学数据预测人体终末相分布容积(Vd(beta))。然后,通过将消除速率常数与Vd(beta)相乘计算总体清除率(CL(tot)),并将BA计算为CL(tot)与口服清除率之比。对67种有人体静脉给药后药代动力学数据的药物,比较预测值与观测值。
对于Vd(beta),方法Ia和Ib(仅使用大鼠药代动力学数据)分别有72.1%的药物预测值在观测值的两倍以内。方法II(使用大鼠以外动物的药代动力学数据)的相应百分比为75.0%。对于BA,方法Ia和Ib分别有66.7%和57.4%的药物预测值在观测值的1.3倍以内,方法II为75.0%。
使用本方法,在不使用静脉注射数据的情况下,结合动物药代动力学数据,从人体口服给药数据预测BA到一定水平是可能的。